Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Antiplatelet agents reported by Lilly

Sep. 13, 1996

Promising phase I data reported for oral heparin

Sep. 13, 1996

First human trial for transgenic product

Sep. 13, 1996

Genetics Institute's recombinant factor IX submitted for approval

Sep. 6, 1996

Monoclonal antibody for thrombotic disorders from Teijin

Sep. 6, 1996

Roche and Genentech prepare prodrugs of fibrinogen antagonist

Sep. 6, 1996

Bayer's new cGMP PDE inhibitors

Sep. 6, 1996

Hisamitsu describes platelet aggregation inhibitors

Sep. 6, 1996

Antiplatelet agents described by Kissei

Aug. 30, 1996

TxA2/PGH2 antagonists described by Terumo

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...